Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 17 May 2022
Governor Hochul announces new watchdog bureau to tackle prescription drug costs
11 May 2022 - New pharmacy benefits bureau to supervise unregulated pharmacy benefit manager industry. ...
Posted by Michael Wonder on 17 May 2022
Finerenone for treating chronic kidney disease in people with type 2 diabetes
17 May 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 17 May 2022
International regulators and WHO: support health care professionals to enhance public confidence in COVID-19 vaccines
17 May 2022 - the EMA has endorsed a statement for health care professionals jointly developed by the International Coalition ...
Posted by Michael Wonder on 17 May 2022
The drugs that give her life cost more than half the family's income
18 May 2022 - For Vickie Hudson-Craig, this year’s Budget could mean the difference between life and death. ...
Posted by Michael Wonder on 17 May 2022
FDA authorises first COVID-19 test available without a prescription that also detects influenza and RSV
16 May 2022 - The EUA authorises at home sample collection with testing performed in a laboratory. ...
Posted by Michael Wonder on 17 May 2022
MHRA marketing authorisation granted for Eli Lilly’s Verzenios as early breast cancer treatment
17 May 2022 - Authorisation of the treatment is based on results from the Phase 3 trial. ...
Posted by Michael Wonder on 17 May 2022
Valneva receives notice of European Commission’s intent to terminate COVID-19 vaccine purchase agreement
16 May 2022 - Valneva today announced that it has received a notice from the European Commission of intent to ...
Posted by Michael Wonder on 17 May 2022
Discount rate adjustment for the health of future generations
17 May 2022 - Medicines Australia has released a video detailing the need for Australia to adjust its discount rate ...
Posted by Michael Wonder on 16 May 2022
Pfizer settles two lawsuits, starts another over etanercept biosimilar in Australia
17 May 2022 - After agreeing to settle with Amgen over its oncology biosimilars, Pfizer issued a new patent lawsuit ...
Posted by Michael Wonder on 16 May 2022
Korea clears permit for Samsung Bioepis’ Lucentis biosimilar after US
16 May 2022 - Samsung Bioepis received marketing approval for Amelivu (ranibizumab), a biosimilar referencing Lucentis to treat various eye ...
Posted by Michael Wonder on 16 May 2022
EMA publishes agenda for 16-19 May 2022 CHMP meeting
16 May 2022 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 16 May 2022
Sun Pharma announces US FDA approval for generic mesalamine extended release capsules
12 May 2022 - Sun Pharmaceutical Industries today announced that it has received final approval from U.S. FDA for its ...
Posted by Michael Wonder on 16 May 2022
Japan pharma lobbies say pricing scheme leading to renewed 'drug lag'
16 May 2022 - Japan's three major pharmaceutical lobbies joined for the first time on Monday in urging reforms to ...
Posted by Michael Wonder on 16 May 2022
AARP ‘people’s hearing’ will highlight Rx struggles
16 May 2022 - Congress will hear how high prescription drug prices affect older Americans. ...
Posted by Michael Wonder on 16 May 2022
FDA rejects anti-depressant seen as possible COVID-19 treatment
16 May 2022 - The FDA declined Monday to authorise a 30 year old generic anti-depressant as a treatment for ...